KALA BIO, Inc. — Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 —— Exploring opportunities to expand KPI-012 into additional corneal indications —— Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected